Aquinnah Pharmaceuticals

Executive Summary

Aquinnah Pharmaceuticals is a private, pre-clinical biotechnology company pioneering a novel approach to treating neurodegenerative diseases by targeting pathological biomolecular condensates, specifically stress granules. Based in Cambridge, MA and founded in 2014, the company is developing orally administered small molecules for conditions such as ALS and Alzheimer's disease. Its platform stems from foundational research linking RNA-binding proteins and stress granule dynamics to neurodegeneration. While Aquinnah has not disclosed total funding or valuation, its focus on a cutting-edge mechanism—modulating stress granules—positions it in a competitive but high-risk space. The company's pre-clinical stage means it has yet to enter human trials, and its private status limits public visibility. However, if successful, its therapeutics could address significant unmet needs in neurodegenerative diseases where few disease-modifying treatments exist. The company's progress will depend on securing additional funding, generating compelling preclinical data, and advancing toward investigational new drug (IND) application.

Upcoming Catalysts (preview)

• Q1 2026Preclinical data release in ALS or Alzheimer's models55% success
• Q3 2026IND-enabling studies completion30% success
• TBDPartnership or licensing deal with larger pharma25% success